MustangBio
mustangbio.com
Actively hiring
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$196.8M
5 rounds on record
Latest round
$2.5M
Convertible Note · Jun 2024 · 2 yr ago
Backers
2
Horizon Technology Finance, Runway Growth Capital
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 19, 2024
Raised a round Convertible Note $2.5M · SEC Form D
Oct 26, 2023
Raised a round Venture round $4.7M · SEC Form D
Mar 31, 2017
Raised a round Venture round $416k · SEC Form D
Sep 30, 2016
Raised a round Venture round $94.6M · SEC Form D
Sep 30, 2016
Raised a round Venture round $94.6M · SEC Form D
2015
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Convertible Note | Jun 2024 | $2.5M | — | SEC Form D |
| Venture round | Oct 2023 | $4.7M | — | SEC Form D |
| Venture round | Mar 2017 | $416k | — | SEC Form D |
| Venture round | Sep 2016 | $94.6M | — | SEC Form D |
| Venture round | Sep 2016 | $94.6M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | MUSTANG BIO, INC. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Michael WeissDirectorSEC Form D
Manuel Litchman M.D.Executive Officer, DirectorSEC Form D
Eliot LurierExecutive OfficerSEC Form D
James MurphyExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Horizon Technology Finance 
Runway Growth Capital Similar startupsby what they do, their industry and backers
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company.
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…
Leading the future of targeted therapies for the hardest to treat cancers. Wednesday, October 15, 202512:00 pm ET.
Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of…
Neurogastrx, Inc.. Thank you for visiting the website for Neurogastrx, Inc. ("Company"), a privately held, late clinical-stage…
Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.
News
Mustang Bio's CAR-T MB-106 Achieves Responses in Waldenstrom Macroglobulinemia, Follicular Lymphoma CGTlive
Two of 6 patients in the WM cohort achieved a complete response and 16 of 20 patients in the FL cohort achieved a complete response.
Read more
Report
MB-106 Shows Potential in Indolent Lymphoma CGTlive
Mustang reported new data and responses from a multicenter phase 1 trial evaluating its CAR T-cell therapy in patients with NHL, FL, and WM.
Read more
Report
Mustang Bio's CAR/Oncolytic Virus Combo Cleared for Glioblastoma/Astrocytoma Trial CGTlive
The combo, termed MB-109, consists of the MB-108 oncolytic virus and MB-101 CAR T-cell therapy.
Read more
Report
Mazyar Shadman, MD, on Evaluating MB-106 in a Multicenter Study CGTlive
The associate professor at Fred Hutch Cancer Center discussed new data on the CD20-targeting CAR he presented at ASH 2023.
Read more
Report
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial,
Mustang Bio, City of Hope CAR-T therapy extends survival in phase 1 glioblastoma trial , Fierce Biotech, March 12, 2024
Read more
Report
Pro access
Upgrade to see all 13 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Michael Weiss
Director
Manuel Litchman M.D.
Executive Officer, Director
Eliot Lurier
Executive Officer
James Murphy
Executive Officer
Lindsay Rosenwald
Director
Neil Herskowitz
Director
Adam Chill
Director
Lindsay Rosenwald M.D.
Director
Michael Zelefsky M.D.
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
New York
United States
HQ
Waltham
United States
Regional office
RSS News Feed
95 Sawyer Road, Suite 110 • Waltham, MA 02453
Financials
Total raised
$196.8M
Latest round
Convertible Note
Funding rounds
5